Overall, these results demonstrate that CLC3 overexpression promotes tumor growth and confers resistance to cisplatin, whereas CLC3 depletion enhances chemosensitivity, reduces tumor growth, and inhibits metastases in vivo. This evidence concerns the gene CLCN3 and neoplasm.